Status:
RECRUITING
Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
Lead Sponsor:
The Second Hospital of Shandong University
Conditions:
Esophageal Cancer
Gastroesophageal Cancer
Eligibility:
All Genders
25-80 years
Phase:
NA
Brief Summary
Surgery with or without neoadjuvant therapy is usually used as the treatment for resectable esophageal cancer or esophageal- gastric junction cancer. Patients who have a poor response to neoadjuvant t...
Eligibility Criteria
Inclusion
- Histologically proven esophageal or EG-junction carcinoma (Siewert I-II). The heart and lung function can tolerate surgery. The cancer is resectable and incurable therapy will be perfomed.
Exclusion
- EG-junction carcinoma (Siewert III). M1 stage according to the current (8th) version of TNMclassification system. The heart and lung function can't tolerate surgery. R2 Resection Status.
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04688801
Start Date
July 1 2020
End Date
December 31 2027
Last Update
November 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Hospital of Shandong University
Jinan, Shandong, China, 250033